GlassScriptPhysician profile
Carl A Ogas
NPI 1467539940
$6,011.62
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,090 · 2020: $1,251 · 2021: $1,652 · 2022: $1,755 · 2023: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $231 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $231.20 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,207.19 | 2019-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $1,185.31 | 2019-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $540.53 | 2019-2022 | |
| Amgen INC. | $406.81 | 2020-2023 | Otezla, Repatha |
| Philips North America LLC | $364.51 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $341.99 | 2021-2023 | |
| Pfizer INC. | $316.85 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.74 | 2019-2023 | Stiolto Respimat, Spiriva Respimat, Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $178.31 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $153.92 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $150.23 | 2021 | |
| Merck Sharp & Dohme LLC | $146.13 | 2019-2022 | |
| Abbvie INC. | $138.26 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $118.89 | 2019-2021 | |
| Horizon Therapeutics Plc | $113.36 | 2019-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $91.74 | 2021-2023 | Trelegy Ellipta |
| Allergan, INC. | $82.04 | 2020 | |
| Novartis Pharmaceuticals Corporation | $67.27 | 2019-2022 | |
| Radius Health, INC. | $57.15 | 2019-2021 | |
| Dexcom, INC. | $23.21 | 2022 | |
| Medtronic Minimed, INC. | $20.13 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.58 | 2019 | |
| Astellas Pharma US INC | $13.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Ogas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.